Cancer Cell · 2013 · 190 citations · 25 references
MedicineCancer BiologyOncologyCarcinogenesisMolecular OncologyTumor ProgressionCancer Cell SignalingCancer ProgressionLung CancerOncogenic Signaling PathwaysRas Family OncogenesTumor Suppressor GenesMek InhibitionMek InhibitorsPi3k InhibitorsPi3k SignalingRas Resistance MechanismsRas-driven Tumorigenesis
RAS proteins directly activate PI3-kinases. Mice bearing a germline mutation in the RAS binding domain of the p110α subunit of PI3-kinse are resistant to the development of RAS-driven tumors. However, it is unknown whether interaction of RAS with PI3-kinase is required in established tumors. The need for RAS interaction with p110α in the maintenance of mutant Kras-driven lung tumors was explored using an inducible mouse model. In established tumors, removal of the ability of p110α to interact with RAS causes long-term tumor stasis and partial regression. This is a tumor cell-autonomous effect, which is improved significantly by combination with MEK inhibition. Total removal of p110α expression or activity has comparable effects, albeit with greater toxicities.
25
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi et al. · New England Journal of Medicine · 2010 · 5.6K citations
Medicine, Oncology, Pharmacology +13
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa et al. · New England Journal of Medicine · 2013 · 3.4K citations · Full text
Medicine, Oncology, Pharmacology +15
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice
Leisa Johnson, Kim L. Mercer, Doron C. Greenbaum et al. · Nature · 2001 · 1.2K citations